Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study has a phase 1 and a phase 2 component.
In phase 1, the objective is to determine the maximum tolerated dose (MTD) of lenalidomide
when after azacitidine.
In phase 2, the objective is to determine the efficacy of the combination treatment.